Abstract 3962: Knocked Down Mir-221/222 Inhibits Akt Pathway to Suppress Malignant Glioma Cell Growth Independent of PTEN Status
Chunzhi Zhang,Anling Zhang,Jianwei Hao,Junxia Zhang,Zhifan Jia,Guangxiu Wang,Peiyu Pu,Chunsheng Kang
DOI: https://doi.org/10.1158/1538-7445.am2011-3962
IF: 11.2
2011-01-01
Cancer Research
Abstract:Abstract MicroRNAs (miRNAs) are a class of endogenous small noncoding RNAs that regulate gene expression after transcription. By base-pairing with the complementary sites in the 3’untranslated region (3’UTR) of the mRNA, miRNAs control mRNA stability and translation efficiency. Aberrant expression of miRNAs have been shown to be involved in tumorigenesis. MiR-221 and miR-222 were frequently overexpressed in human malignant tumor, including glioblastoma. By Northern Blot assay, we found that miR-221 and miR-222 upregulated in glioma cell lines. In addition, Akt pathway is aberrant activity in glioblastoma. Our work have proved that miR-221/222 promote malignant progression of glioma cell through activation of the Akt pathway. Once Akt activated, it promotes cellular proliferation and invasion ability and reduces cell apoptosis and radiosensitivity. By bioinformation analysis, we found that PTEN is a target of miR-221 and miR-222. By luciferase report assay, we identified that PTEN is a target of miR-221 and miR-222. It is unknown whether miR-221/222 activate Akt pathway dependent of PTEN status or not. We knocked down miR-221/222 with a specific antisense oligonucleotide and found that phenotype of glioblastoma cell changed in vitro in U251 (PTEN mutant) and LN229 (PTEN wild type), including increasing cell proliferation and invasion ability, reducing cell apoptosis and radiosensitivity. By Western Blot, knocked down miR-221/222-cells showed a decreased expression of EGFR, activated Akt, cyclin D, and Bcl-2. Furthermore, knockeddown miR-221/222 considerably decreased tumor growth in U251 cell xenograft model. By immunofluorescence assay, it was found that antisense-miR-221/222 significantly knocked down miR-221 and miR-222 in vivo. By Tunnel assay, antisense-miR-221/222 significantly increased cell apoptosis in vivo. By immunohistochemistry staining, some protein expression reduced, including expression of EGFR, activated Akt, cyclin D, and Bcl-2. Although miR-221 /222 is known to regulate PTEN and downregulation of miR-221/222 led to increased PTEN expression endogenously, the GBM suppressor effect of antisense-miR-221/222 is most likely independent of PTEN regulation because U251 has mutant PTEN. Taken together, our studies provide evidence that miR-221/222 may serve as a novel therapeutic target for malignant gliomas independent of PTEN status. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3962. doi:10.1158/1538-7445.AM2011-3962